Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.

deBruyn JC, Huynh HQ, Griffiths AM, Jacobson K, Mack D, Deslandres C, El-Matary W, Otley AR, Church PC, Lawrence S, Wine E, Sherlock M, Critch J, Benchimol EI, Jantchou P, Rashid M, Carroll MW, Bax K, Ricciuto A, Carman N, Walters TD, and the Canadian Children IBD Network

Open source

DOI: 10.14309/ajg.0000000000002552
Published: 2024 Mar 1
Container: The American journal of gastroenterology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.14309/ajg.0000000000002552,
  title = {Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.},
  author = {deBruyn JC and Huynh HQ and Griffiths AM and Jacobson K and Mack D and Deslandres C and El-Matary W and Otley AR and Church PC and Lawrence S and Wine E and Sherlock M and Critch J and Benchimol EI and Jantchou P and Rashid M and Carroll MW and Bax K and Ricciuto A and Carman N and Walters TD and and the Canadian Children IBD Network},
  year = {2024},
  journal = {The American journal of gastroenterology},
  doi = {10.14309/ajg.0000000000002552},
  url = {https://doi.org/10.14309/ajg.0000000000002552}
}

RIS

TY  - JOUR
TI  - Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
AU  - deBruyn JC
AU  - Huynh HQ
AU  - Griffiths AM
AU  - Jacobson K
AU  - Mack D
AU  - Deslandres C
AU  - El-Matary W
AU  - Otley AR
AU  - Church PC
AU  - Lawrence S
AU  - Wine E
AU  - Sherlock M
AU  - Critch J
AU  - Benchimol EI
AU  - Jantchou P
AU  - Rashid M
AU  - Carroll MW
AU  - Bax K
AU  - Ricciuto A
AU  - Carman N
AU  - Walters TD
AU  - and the Canadian Children IBD Network
PY  - 2024
JO  - The American journal of gastroenterology
DO  - 10.14309/ajg.0000000000002552
UR  - https://doi.org/10.14309/ajg.0000000000002552
ER  -

APA

JC, D., HQ, H., AM, G., K, J., D, M., C, D., W, E., AR, O., PC, C., S, L., E, W., M, S., J, C., EI, B., P, J., M, R., MW, C., K, B., A, R., N, C., TD, W., & Network, A. T. C. C. I. (2024). Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.. The American journal of gastroenterology. https://doi.org/10.14309/ajg.0000000000002552

Source records

pubmed · retrieved 2026-09-26T16:53:40.934Z